It is known that β‐catenin degradation is mediated by the Axin/APC/GSK3β complex when Wnt signalling is not activated,5, 6 and that Zbed3 may regulate β‐catenin by interacting with Axin and inhibiting the function of Axin/APC/GSK3β complex.10 Consistent with that finding, abnormal Axin expression or function has been seen in various malignancies, including NSCLC.8, 9 We therefore investigated the effects of Zbed3 on β‐catenin levels and cancer cell proliferation and invasiveness as it relates to Axin/APC/Gsk3β complex function. Here, GSK3B is linked to non-small cell lung carcinoma.